Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Indiana: - Franciscan Health Indianapolis — Indianapolis, Indiana
- Franciscan Saint Elizabeth Health - Lafayette East — Lafayette, Indiana
- Franciscan Health Mooresville — Mooresville, Indiana
- Reid Health — Richmond, Indiana
- Union Hospital — Terre Haute, Indiana
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Goshen Center for Cancer Care — Goshen, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- IU Health Methodist Hospital — Indianapolis, Indiana
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
- Ascension Saint Vincent Indianapolis Hospital — Indianapolis, Indiana
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Indiana: - Community Cancer Center North — Indianapolis, Indiana
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Indiana: - Indiana University — Indianapolis, Indiana
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Indiana: - Reid Health — Richmond, Indiana
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Indiana: - Indiana University Riley Children's Hospital — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated…
Sponsor: Scott R. Plotkin, MD, PhD
NCT ID: NCT04374305
Sites in Indiana: - Indiana University School of Medicine — Indianopolis, Indiana
Phase 1 Recruiting Network
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…
Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 1 Recruiting Academic/Other
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06934889
Sites in Indiana: - Indiana University (Data Collection Only) — Indianapolis, Indiana
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Indiana: - Goodman Campbell Brain and Spine — Carmel, Indiana
- Indiana University, IU Health Methodist Hospital — Indianapolis, Indiana